In metastatic castrate-sensitive prostate cancer standard of care was either medical or surgical castration along with ADT, in high volume, disease docetaxel was approved based on the CHAARTED trial. However bone-directed therapy was not showing any benefit [zolendronic acid] based on so far available evidence [ALLIANCE-CALGB 90202].
Now another milestone in castrate-sensitive prostate cancer is an addition of abiraterone to Androgen deprivation therapy in newly diagnosed, metastatic, castration-sensitive prostate cancer based on LATITUDE trial. This trial was a double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 patients to receive either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy plus dual placebos (the placebo…
